PRESS RELEASE published on 05/22/2025 at 01:15, 1 year 1 month ago Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist Alzheimer's Disease Sanofi Neurology Vigil Neuroscience VG-3927
BRIEF published on 05/15/2025 at 19:11, 1 year 1 month ago Sanofi : Détails sur les Droits de Vote et Actions - Avril 2025 Investissement Droits De Vote Actions Sanofi Avril 2025
BRIEF published on 05/15/2025 at 19:11, 1 year 1 month ago Sanofi: Details on Voting Rights and Shares - April 2025 Voting Rights Actions Investment Sanofi April 2025
PRESS RELEASE published on 05/15/2025 at 19:06, 1 year 1 month ago Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2025 Publication des droits de vote et actions de Sanofi selon les réglementations financières en vigueur Autorité Des Marchés Financiers Droits De Vote Code De Commerce Actions Sanofi
BRIEF published on 04/30/2025 at 13:05, 1 year 1 month ago Sanofi et CD&R finalisent la cession d'Opella Cession Sanofi CD&R Opella Santé Grand Public
BRIEF published on 04/30/2025 at 13:05, 1 year 1 month ago Sanofi and CD&R finalize the sale of Opella Sanofi CD&R Assignment Opella Consumer Health
PRESS RELEASE published on 04/30/2025 at 13:00, 1 year 1 month ago Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public Sanofi finalise la cession d'Opella à CD&R, créant un leader mondial de la santé grand public. Opella devient un champion indépendant avec l'appui de CD&R et conserve une participation de 48,2% Cession Sanofi CD&R Opella Santé Grand Public
PRESS RELEASE published on 04/30/2025 at 13:00, 1 year 1 month ago Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion Transaction Sanofi CD&R Consumer Healthcare Opella
BRIEF published on 04/08/2025 at 19:15, 1 year 2 months ago Sanofi : Publication Positive des Données du Tolebrutinib dans le NEJM Sclérose En Plaques Sanofi Phase III NEJM Tolebrutinib
BRIEF published on 04/08/2025 at 19:15, 1 year 2 months ago Sanofi: Positive Publication of Tolebrutinib Data in NEJM Multiple Sclerosis Sanofi Phase III NEJM Tolebrutinib
Published on 06/26/2026 at 01:40, 10 hours 29 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 12 hours 39 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 13 hours 39 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 14 hours 37 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 20 hours 39 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 11:14, 54 minutes ago EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
Published on 06/26/2026 at 11:05, 1 hour 4 minutes ago Join the Beautiful Game: Discover Immersive Fan Experiences with Hisense at FIFA World Cup 2026™
Published on 06/26/2026 at 10:59, 1 hour 10 minutes ago HELIOS SOLAR AG starts subscription period for Initial Public Offering – shares offered at EUR 4.00
Published on 06/26/2026 at 10:50, 1 hour 18 minutes ago Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership
Published on 06/26/2026 at 07:00, 5 hours 9 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 5 hours 9 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 17 hours 24 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 17 hours 39 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 18 hours 19 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS